

Serial No: 10/826,901

Claim 1 (currently amended) The method of improving FMF control, in humans, which includes administering, on an average daily basis, for at least 5 months, between 5 and 15 milligrams of LTRA to a patient suffering from FMF[[]], for treatment only of FMF.

Claim 2 (original) The method of claim 1 wherein said LTRA is administrated orally.

Claim 3 (original) The method of claim 2 wherein said LTRA is administrated orally in tablet form.

Claim 4 (original) The method of claim 1 wherein about 10 milligrams of said LTRA is administrated, on a daily basis

Claim 5 (original) The method of claim 1 wherein said humans are between 9 and 72 years old.

Claim 6 (original) The method of claim 2 wherein said LTRA consists of ZAFIRLUCAST tablets.

Serial No.10/826,901

Claim 7 (original) The method of claim 2 wherein
said LTRA consists of SINGULAIR tablets.